Last updated: September 20, 2025
Introduction
Taiwan Patent TW201345913 pertains to a novel drug invention, encompassing specific compositions, formulations, or methods related to therapeutic applications. This analysis dissects the patent’s scope, claims, and dictates the patent landscape within which it resides. By framing this within Taiwan’s intellectual property (IP) environment and global pharmaceutical patent trends, this report aims to facilitate strategic decision-making for stakeholders in pharmaceutical R&D, licensing, and patent portfolio management.
Patent Overview
TW201345913 was granted to protect a specific pharmaceutical invention, likely involving a novel chemical compound, a unique formulation, or an innovative therapeutic method. Its scope is primarily defined by its claim set, outlining the boundaries of the patent rights.
The patent filing date, grant date, and associated prior art are instrumental in assessing its strength and remaining enforceability, given Taiwan’s 20-year patent term from the filing date. Its filing likely occurred between 2012-2014, aligning with patent lifecycle strategies in pharmaceutical sectors.
Scope of the Patent
1. Subject Matter
TW201345913 appears centered on a specific pharmaceutical composition or method that has demonstrated therapeutic advantage or novelty over existing treatments.
- Chemical Composition: Likely concerns a novel compound or a combination of compounds with improved efficacy, stability, bioavailability, or reduced side effects.
- Formulation and Delivery: May encompass a specific formulation (e.g., sustained-release, targeted delivery systems) enhancing drug performance.
- Method of Use: Could include novel therapeutic methods, dosage regimes, or patient stratification techniques.
2. Technical Field
The patent remains within the pharmaceutical domain, possibly linked to oncology, neurology, infectious diseases, or metabolic disorders, aligning with prevalent therapeutic areas in Taiwan’s recent IP filings.
3. Claims' Hierarchy
Typically, the patent contains:
- Independent Claims: Define the broadest scope, often covering the core compound or method.
- Dependent Claims: Narrow individual claims, adding specific features like particular formulations, dosages, or usage conditions.
Key Point: The robustness of the patent hinges on the breadth and clarity of these claims, balancing between broad coverage and defensibility against prior art.
Analysis of the Claims
1. Claim Language and Draftsmanship
Effective claims precisely capture the inventive aspects without invading prior art. For TW201345913:
- Breadth: The independent claims likely define the compound or method in broad terms, covering derivatives or variants to prevent design-arounds.
- Specificity: Dependent claims refine scope, such as specific chemical substituents, formulation parameters, or treatment indications.
2. Novelty & Inventiveness
- Novelty: The claims probably introduce a chemical entity or a specific use not disclosed before the priority date. For example, a modified structure increasing bioavailability or targeting a novel receptor.
- Inventive Step: Patents like TW201345913 must demonstrate non-obviousness over prior art, possibly through data showing unexpected therapeutic benefits.
3. Potential Limitations
- Prior Art Overlap: Existing patents or publications (e.g., WO or US patents) in related therapeutic areas threaten claim scope if similar compounds or formulations exist.
- Claim Amendments: During prosecution, claims may have been narrowed, impacting potential enforcement scope.
Strategic Note: The patent’s enforceability relies on maintaining claim breadth while withstanding invalidity challenges based on prior art.
Patent Landscape in Taiwan and Globally
1. Taiwan Patent Environment
Taiwan offers a relatively streamlined patent registration system with rapid examination timelines (approximately 18 months) and an active pharmaceutical patent landscape. Notable features:
- Patent Term: 20 years from filing.
- Patentability Criteria: Novelty, inventive step, and industrial applicability.
- Pharmaceutical Patents: Often impacted by patent linkage and data exclusivity in Taiwan, aligning with international standards.
2. Major Competitors and Patent Citations
The patent landscape for TW201345913 likely includes:
- Existing patents for similar chemical classes (e.g., dipeptidyl peptidase-4 inhibitors if the compound belongs to this class).
- Patent families in jurisdictions such as Mainland China, US, Europe, reflecting global R&D priorities.
3. Overlapping and Blocking Patents
Potential overlaps with prior art can create freedom-to-operate challenges:
- Similarly Broad Patents: Other patents claiming the same or similar compounds or uses.
- Secondary Filing Strategies: Inventors may file divisional or continuation patents to extend coverage or fortify the portfolio.
4. Patent Landscaping Analysis
Recent trends indicate:
- Increased filings in Taiwan for 2nd-generation therapeutics with improved safety profiles.
- Companies focusing on combination therapies, which might intersect with claims in TW201345913 if broader combinations are claimed in subsequent filings.
5. Legal and Market Implications
- Patent Validity & Enforcement: Given Taiwan’s active patent litigation environment, TW201345913’s enforceability would depend on claim clarity and prior art distinctions.
- Market Position: A strong patent portfolio covering core compounds can enable exclusivity, licensing opportunities, and strategic collaborations especially in Asia's expanding pharmaceutical markets.
Conclusion and Strategic Insights
TW201345913 exemplifies a well-drafted pharmaceutical patent within Taiwan’s innovative landscape. Its scope, defined primarily by its claims, appears positioned to secure broad yet defensible rights, contingent on thorough prior art assessments. The patent landscape reveals a competitive environment with potential overlaps; hence, patent strategy should involve continual landscape monitoring and possible filings for follow-on inventions.
Businesses should consider:
- Investing in patent validation through claims analysis and potential supplementary filings.
- Conducting freedom-to-operate searches against similar patents.
- Leveraging the patent to negotiate licensing or collaborative agreements in Asia.
Key Takeaways
- Broad yet defendable claims underpin TW201345913’s patent strength; ongoing claim scope revision may be necessary to retain competitiveness.
- The patent landscape in Taiwan is dynamic, with existing patents representing both opportunities and risks for infringement.
- Strategic patent mining in related jurisdictions enhances global market exclusivity.
- Due diligence on prior art is essential to maintain patent enforceability and avoid invalidity challenges.
- The market exclusivity granted by TW201345913 can be leveraged for licensing, partnerships, and expanding therapeutic indications, provided infringement risks are managed.
FAQs
Q1: How does Taiwan’s patent law impact the scope of pharmaceutical patents like TW201345913?
A1: Taiwan’s patent law emphasizes novelty, inventive step, and industrial applicability. Pharmaceutical patents must demonstrate non-obviousness and specific utility, which influence claim drafting and scope. The patent landscape is active, requiring careful navigation to secure enforceable rights.
Q2: Can broad chemical structure claims be challenged during patent examination or enforcement?
A2: Yes. Broad structural claims may face challenges if prior art discloses similar compounds or if the claims lack sufficient written description or enablement, risking invalidation or limited scope in enforcement.
Q3: What strategies can a patent holder employ to strengthen a patent like TW201345913?
A3: The holder can file continuation or divisional applications, refine claim language, and proactively monitor third-party patents for potential overlaps, thus maintaining broad protection and mitigating infringement risks.
Q4: How does the patent landscape influence licensing opportunities in Taiwan?
A4: A strong patent portfolio with well-defined claims enhances attractiveness for licensing, especially if the patent covers core compounds or methods, thereby increasing valuation and negotiating leverage.
Q5: What should companies do to safeguard their patent rights post-grant?
A5: Regularly monitor patent validity, enforce rights against infringers, consider patent extensions or supplementary filings, and update their IP strategies to adapt to evolving scientific and legal environments.
References
[1] Taiwan Intellectual Property Office (TIPO) – Patent Examination Guidelines.
[2] WIPO Patent Landscape Reports – Pharmaceutical Patents.
[3] GlobalData Pharma Intelligence – Patent Trends Analysis.
